Reclast Injection, Solution
Product Images NDC 66758-155

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Reclast (NDC 66758-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Image 01)

Packaging label for Reclast (zoledronic acid) injection 5 mg/100 mL, a solution for intravenous infusion. The label shows the product name, strength, dosage form, administration route, and clarifies that it is a sterile solution. The manufacturer is Sandoz Inc. The label advises dispensing the accompanying Medication Guide to each patient and designates the product as Rx only.*

FDA Label Image

Zoledronic Acid Structural Formula (Reclast 01)

Chemical structure of zoledronic acid, the active ingredient in Reclast 5 mg/100 mL injection solution by Sandoz Inc. The structure features a nitrogen-containing heterocyclic ring and two phosphonic acid groups.*

FDA Label Image

Figure 1. Cumulative Incidence Of Hip Fracture Over 3 Years (Reclast 02)

A line graph comparing time to first hip fracture over months between Reclast (zoledronic acid) and placebo groups. The x-axis represents time in months (0 to 36), and the y-axis shows cumulative incidence. Reclast group shows lower incidence than placebo. The graph includes a p-value from a stratified log-rank test (0.0024).*

FDA Label Image

Figure 2. Therapeutic Response/serum Alkaline Phosphatase (sap) Normalization Over Time (Reclast 03)

Two bar graphs comparing Reclast and Risedronate over time. The left graph shows therapeutic response rates (%) at 10, 28, 63, 91, and 182 days, with Reclast showing higher response rates at later time points. The right graph shows serum alkaline phosphatase (SAP) normalization rates (%) over the same time points, indicating higher normalization rates for Reclast at 63, 91, and 182 days. Asterisks mark statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.